PE20231439A1 - Proteinas f de hmpv estabilizadas por prefusion - Google Patents
Proteinas f de hmpv estabilizadas por prefusionInfo
- Publication number
- PE20231439A1 PE20231439A1 PE2023001803A PE2023001803A PE20231439A1 PE 20231439 A1 PE20231439 A1 PE 20231439A1 PE 2023001803 A PE2023001803 A PE 2023001803A PE 2023001803 A PE2023001803 A PE 2023001803A PE 20231439 A1 PE20231439 A1 PE 20231439A1
- Authority
- PE
- Peru
- Prior art keywords
- modified
- protein
- seq
- metapneumovirus
- prefusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a una proteina modificada que comprende un ectodominio de proteina F de metapneumovirus humano (hMPV) estabilizadas por prefusion, que tiene al menos 90 % de identidad con (i) los aminoacidos 19 a 489 de cualquiera de las SEQ ID NO: 1, 2 y 4 a 7, o (ii) los aminoacidos 19 a 484 de la SEQ ID NO: 3, dicha proteina modificada comprende al menos una mutacion relativa a la secuencia de cualquiera de las SEQ ID NO: 1 a 7, dicha al menos una mutacion comprende una sustitucion en una posicion correspondiente a: K166, N342, A/D185, K188, entre otros. Tambien se refiere un trimero de proteina F de metapneumovirus (MPV) modificado que comprende al menos una subunidad, a una molecula de acido nucleico que comprende una secuencia de nucleotidos que codifica una secuencia de aminoacidos de dicha proteina modificada, una composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y (i) la proteina modificada o (ii) el trimero modificado; y su uso en el tratamiento o la prevencion de una infeccion por metapneumovirus (MPV).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089978P | 2020-10-09 | 2020-10-09 | |
| PCT/US2021/053944 WO2022076669A1 (en) | 2020-10-09 | 2021-10-07 | Prefusion-stabilized hmpv f proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231439A1 true PE20231439A1 (es) | 2023-09-14 |
Family
ID=81125547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001803A PE20231439A1 (es) | 2020-10-09 | 2021-10-07 | Proteinas f de hmpv estabilizadas por prefusion |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11919927B2 (es) |
| EP (1) | EP4225364A4 (es) |
| JP (2) | JP7660671B2 (es) |
| KR (1) | KR20230084201A (es) |
| CN (1) | CN116615235A (es) |
| AU (1) | AU2021357826A1 (es) |
| CA (1) | CA3195015A1 (es) |
| CO (1) | CO2023005373A2 (es) |
| IL (2) | IL320367A (es) |
| MX (1) | MX2023004078A (es) |
| PE (1) | PE20231439A1 (es) |
| WO (1) | WO2022076669A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022103967A1 (en) | 2020-11-13 | 2022-05-19 | Icosavax, Inc. | Protein-based nanoparticle vaccine for metapneumovirus |
| WO2023110618A1 (en) * | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| JP2025521082A (ja) * | 2022-05-12 | 2025-07-08 | エムエスディー インターナショナル ビジネス ゲーエムベーハー | 安定化融合前ｈｍｐｖ融合タンパク質 |
| EP4578878A1 (en) * | 2022-09-29 | 2025-07-02 | Beijing Benewill Technology Development Co., Ltd. | Respiratory syncytial virus recombinant fusion protein having pre-fusion conformation, and preparation method therefor and use thereof |
| AU2024209772A1 (en) | 2023-01-18 | 2025-06-26 | Pfizer Inc. | Vaccines against respiratory diseases |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7449324B2 (en) | 2002-02-21 | 2008-11-11 | Vironovative Bv | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| CA2902877A1 (en) | 2013-03-13 | 2014-10-02 | Jeffrey Boyington | Prefusion rsv f proteins and their use |
| US10420834B2 (en) * | 2014-12-24 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus F proteins and their use |
| EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018187325A1 (en) | 2017-04-04 | 2018-10-11 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| JP2021526026A (ja) * | 2018-06-08 | 2021-09-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 翻訳後修飾が低減したペプチドリンカー |
| PE20220400A1 (es) | 2019-05-20 | 2022-03-22 | Valneva Se | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio |
| CN116096407A (zh) * | 2020-04-29 | 2023-05-09 | 美国政府(由卫生和人类服务部的部长所代表) | 重组人偏肺病毒f蛋白及其用途 |
| WO2021252688A1 (en) * | 2020-06-09 | 2021-12-16 | Icosavax, Inc. | Method of assemblying two-component virus-like particle |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
-
2021
- 2021-10-07 KR KR1020237014520A patent/KR20230084201A/ko active Pending
- 2021-10-07 IL IL320367A patent/IL320367A/en unknown
- 2021-10-07 CN CN202180075353.6A patent/CN116615235A/zh active Pending
- 2021-10-07 CA CA3195015A patent/CA3195015A1/en active Pending
- 2021-10-07 JP JP2023521506A patent/JP7660671B2/ja active Active
- 2021-10-07 MX MX2023004078A patent/MX2023004078A/es unknown
- 2021-10-07 EP EP21878525.1A patent/EP4225364A4/en active Pending
- 2021-10-07 WO PCT/US2021/053944 patent/WO2022076669A1/en active Application Filing
- 2021-10-07 AU AU2021357826A patent/AU2021357826A1/en active Pending
- 2021-10-07 PE PE2023001803A patent/PE20231439A1/es unknown
- 2021-10-07 IL IL301950A patent/IL301950B1/en unknown
-
2023
- 2023-04-06 US US18/296,771 patent/US11919927B2/en active Active
- 2023-04-27 CO CONC2023/0005373A patent/CO2023005373A2/es unknown
-
2024
- 2024-01-12 US US18/411,284 patent/US12077563B2/en active Active
- 2024-07-22 US US18/779,961 patent/US12304930B2/en active Active
-
2025
- 2025-04-01 JP JP2025060230A patent/JP2025102893A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023005373A2 (es) | 2023-05-19 |
| IL301950A (en) | 2023-06-01 |
| US20230357327A1 (en) | 2023-11-09 |
| JP7660671B2 (ja) | 2025-04-11 |
| IL320367A (en) | 2025-06-01 |
| MX2023004078A (es) | 2023-05-24 |
| WO2022076669A1 (en) | 2022-04-14 |
| JP2025102893A (ja) | 2025-07-08 |
| AU2021357826A1 (en) | 2023-05-11 |
| US20240376158A1 (en) | 2024-11-14 |
| CA3195015A1 (en) | 2022-04-14 |
| CN116615235A (zh) | 2023-08-18 |
| EP4225364A4 (en) | 2025-02-26 |
| US12077563B2 (en) | 2024-09-03 |
| AU2021357826A9 (en) | 2023-07-13 |
| US11919927B2 (en) | 2024-03-05 |
| US20240140994A1 (en) | 2024-05-02 |
| EP4225364A1 (en) | 2023-08-16 |
| IL301950B1 (en) | 2025-05-01 |
| JP2023544834A (ja) | 2023-10-25 |
| KR20230084201A (ko) | 2023-06-12 |
| US12304930B2 (en) | 2025-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| ES2533874T3 (es) | Armazón proteico | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| BR0107703A (pt) | Flavivìrus recombinantes e processos para uso dos mesmos | |
| MX2012002216A (es) | Nueva endolisina obpgplys. | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| NO20063026L (no) | Antistoffer | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| AR050050A1 (es) | Factores de virulencia bacteriana y sus usos | |
| EA200401504A1 (ru) | Слитый белок из числа регуляторных/вспомогательных белков вич | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| BRPI0516176A (pt) | polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| PE20251395A1 (es) | Proteinas de fusion de hmpv de prefusion estabilizadas | |
| BR9803960A (pt) | Gene de desidrogenase de d-sorbitol. | |
| BRPI0410562A (pt) | molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| RU2014138418A (ru) | Белки пилей и композиции | |
| AR124310A1 (es) | INMUNOCITOQUINA PARA ACTIVAR EL RECEPTOR IL-10Ra HUMANO Y SU USO |